Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 13.23% and Operating profit at 16.30% over the last 5 years
2
With a fall in Net Sales of -38.1%, the company declared Very Negative results in Mar 25
3
With ROE of 25.02%, it has a very expensive valuation with a 4.46 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 21,483 Million (Large Cap)
18.00
NA
2.21%
-0.10
25.02%
4.46
Revenue and Profits:
Net Sales:
410 Million
(Quarterly Results - Jun 2025)
Net Profit:
-85 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.18%
0%
-16.18%
6 Months
-11.49%
0%
-11.49%
1 Year
-35.3%
0%
-35.3%
2 Years
-34.21%
0%
-34.21%
3 Years
-42.25%
0%
-42.25%
4 Years
-72.98%
0%
-72.98%
5 Years
-45.46%
0%
-45.46%
Sichuan Swellfun Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.23%
EBIT Growth (5y)
16.30%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.91
Tax Ratio
25.38%
Dividend Payout Ratio
35.14%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
92.55%
ROE (avg)
31.60%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
4.46
EV to EBIT
13.98
EV to EBITDA
12.11
EV to Capital Employed
4.86
EV to Sales
5.05
PEG Ratio
NA
Dividend Yield
2.21%
ROCE (Latest)
34.76%
ROE (Latest)
25.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Jun 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
410.40
663.10
-38.11%
Operating Profit (PBDIT) excl Other Income
-126.40
135.70
-193.15%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-84.90
56.10
-251.34%
Operating Profit Margin (Excl OI)
-450.40%
139.50%
-58.99%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -38.11% vs 16.03% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -251.34% vs 29.56% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,420.90
4,176.00
5.86%
Operating Profit (PBDIT) excl Other Income
1,931.10
1,727.00
11.82%
Interest
0.60
1.20
-50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,341.00
1,268.80
5.69%
Operating Profit Margin (Excl OI)
391.20%
386.70%
0.45%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 5.86% vs 6.05% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 5.69% vs 4.36% in Dec 2023
About Sichuan Swellfun Co., Ltd. 
Sichuan Swellfun Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






